Skip to main content

Loading market data...

ONC

BeOne Medicines AG

NASDAQ • United states

$386.46

+$1.96

(+0.51%)

Source: Yahoo Finance · Quote time Oct 21, 2026 20:00 GMT+0000

Management
Credibility
Score

BeOne Medicines AG (ONC)

Unavailable

Quotes may be delayed

$43.94B

Market Cap

548,932

Volume

67.0

P/E Ratio

Unavailable

Div Yield

BeOne Medicines AG Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: C/O BEONE MEDICINES I GMBH, BASEL
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

17 Sep 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in BeOne Medicines Ltd..

26 Aug 2026

BeOne Medicines Ltd. reported Operating or financial results

BeOne Medicines Ltd. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

5 Aug 2026

BeOne Medicines Ltd. filed Form 10-Q

BeOne Medicines Ltd. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

5 Aug 2026

BeOne Medicines Ltd. reported Operating or financial results

BeOne Medicines Ltd. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

26 Jun 2026

BeOne Medicines Ltd. reported Another company event

BeOne Medicines Ltd. filed an 8-K covering another company event.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$5.10B

Total assets (USD)$9.18B

Total liabilities (USD)$4.00B

Shareholders' equity (USD)$5.17B

Long-term debt (USD)$882.16M

Debt due within a year (USD)$190.90M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$1.71B	$325.05M	$237.01M	$0.16	10-Q · 5 Aug 2026
Q1 2026	$1.51B	$249.90M	$227.36M	$0.15	10-Q · 6 May 2026
Q4 2025	$1.50B	$185.04M	$66.50M	Unavailable	10-K · 26 Feb 2026
Q3 2025	$1.41B	$163.11M	$124.84M	$0.08	10-Q · 6 Nov 2025
Q2 2025	$1.32B	$87.89M	$94.32M	$0.06	10-Q · 6 Aug 2025
Q1 2025	$1.12B	$11.10M	$1.27M	$0.00	10-Q · 7 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $427.25

10.6% upside potential

📈

Strong Buy

Unavailable

👍

Buy

13

⏸️

Hold

0

📉

Sell

0

13 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 22 Oct 2026, 02:49 UTC Targets range 370.00–466.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

13

Oct 2026

Wang Xiaodong

Director

Option exercise

$36.90 per share

31,027 shares

13

Oct 2026

Wang Xiaodong

Director

Open-market sale

$350.99 per share

31,027 shares

30

Sep 2026

Lee Chan Henry

SVP, General Counsel

Open-market sale

$375.00 per share

1,115 shares

28

Sep 2026

Wang Xiaodong

Director

Option exercise

$36.90 per share

31,028 shares

28

Sep 2026

Wang Xiaodong

Director

Open-market sale

$364.79 per share

31,028 shares

14

Sep 2026

BAKER BROS. ADVISORS LP

Director

Option exercise

$36.83 per share

61,536 shares

8

Sep 2026

Wang Xiaodong

Director

Open-market sale

$349.10 per share

38,287 shares

8

Sep 2026

Wang Xiaodong

Director

Option exercise

$36.90 per share

31,027 shares

1

Sep 2026

Ball Titus B.

Principal Accounting Officer

Open-market sale

$355.86 per share

132 shares

25

Aug 2026

Wu Xiaobin

President and COO

Open-market sale

$380.00 per share

280 shares

Top Shareholders

Baker Bros. Advisors Lp

8,801,567 shares

0.029% change

6/30/2026

Primecap Management Co/Ca/

5,007,931 shares

0.658% change

6/30/2026

Capital International Investors

4,210,221 shares

1.238% change

6/30/2026

Fmr Llc

2,478,527 shares

-32.897% change

6/30/2026

Capital World Investors

2,249,582 shares

38.633% change

6/30/2026

Citadel Advisors Llc

1,425,517 shares

38.092% change

6/30/2026

Temasek Holdings (Private) Ltd

845,729 shares

-1.961% change

6/30/2026

Price T Rowe Associates Inc /Md/

758,752 shares

40.57% change

6/30/2026

Blackrock, Inc.

694,618 shares

5.645% change

6/30/2026

Millennium Management Llc

543,323 shares

165.235% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 22 Oct 2026, 02:49 UTC· 6 hours ago

Research coverage and investment tools

BeOne Medicines AG (ONC) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$386.46 on 21 Oct 2026. That is 98% of the way from its 52-week low of US$253.95 to its 52-week high of US$388.66. Its market capitalisation was US$43.94 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$1.71B	$325.05M	$237.01M	$0.16	89.8%	19.1%	$435.34M	10-Q · 5 Aug 2026 (opens in a new tab)
Q1 2026	$1.51B	$249.90M	$227.36M	$0.15	89.0%	16.5%	$160.55M	10-Q · 6 May 2026 (opens in a new tab)
Q4 2025	$1.50B	$185.04M	$66.50M	Unavailable	90.5%	12.4%	$379.83M	10-K · 26 Feb 2026 (opens in a new tab)
Q3 2025	$1.41B	$163.11M	$124.84M	$0.08	86.1%	11.5%	$354.47M	10-Q · 6 Nov 2025 (opens in a new tab)
Q2 2025	$1.32B	$87.89M	$94.32M	$0.06	87.5%	6.7%	$219.77M	10-Q · 6 Aug 2025 (opens in a new tab)
Q1 2025	$1.12B	$11.10M	$1.27M	$0.00	85.2%	1.0%	−$12.33M	10-Q · 7 May 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	8/5/2026	$2.05	$1.40	+46.4%
Mar 2026	5/6/2026	$1.96	$0.73	+168.5%
Dec 2025	2/26/2026	$0.58	$1.60	-63.8%
Sep 2025	11/6/2025	$1.09	$0.72	+51.4%

Cash and equivalents: $5.10B
Total assets: $9.18B
Total liabilities: $4.00B
Shareholders' equity: $5.17B
Long-term debt: $882.16M
Debt due within a year: $190.90M

SCHEDULE 13D/A · 17 Sep 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in BeOne Medicines Ltd..
8-K · 26 Aug 2026

BeOne Medicines Ltd. reported Operating or financial results (opens in a new tab)

BeOne Medicines Ltd. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
10-Q · 5 Aug 2026

BeOne Medicines Ltd. filed Form 10-Q (opens in a new tab)

BeOne Medicines Ltd. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 5 Aug 2026

BeOne Medicines Ltd. reported Operating or financial results (opens in a new tab)

BeOne Medicines Ltd. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
8-K · 26 Jun 2026

BeOne Medicines Ltd. reported Another company event (opens in a new tab)

BeOne Medicines Ltd. filed an 8-K covering another company event.

Insider	Date	Transaction	Shares	Average price	Filing
Wang Xiaodong Director	13 Oct 2026	Option exercise (M)	+31,027	$36.90	Form 4 (opens in a new tab)
Wang Xiaodong Director	13 Oct 2026	Open-market sale (S)	−31,027	$350.99	Form 4 (opens in a new tab)
Lee Chan Henry SVP, General Counsel	30 Sep 2026	Open-market sale (S)	−1,115	$375.00	Form 4 (opens in a new tab)
Wang Xiaodong Director	28 Sep 2026	Option exercise (M)	+31,028	$36.90	Form 4 (opens in a new tab)
Wang Xiaodong Director	28 Sep 2026	Open-market sale (S)	−31,028	$364.79	Form 4 (opens in a new tab)
BAKER BROS. ADVISORS LP Director	14 Sep 2026	Option exercise (M)	+61,536	$36.83	Form 4 (opens in a new tab)
Wang Xiaodong Director	8 Sep 2026	Open-market sale (S)	−38,287	$349.10	Form 4 (opens in a new tab)
Wang Xiaodong Director	8 Sep 2026	Option exercise (M)	+31,027	$36.90	Form 4 (opens in a new tab)
Ball Titus B. Principal Accounting Officer	1 Sep 2026	Open-market sale (S)	−132	$355.86	Form 4 (opens in a new tab)
Wu Xiaobin President and COO	25 Aug 2026	Open-market sale (S)	−280	$380.00	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Baker Bros. Advisors Lp	6/30/2026	8,801,567	0.029%
Primecap Management Co/Ca/	6/30/2026	5,007,931	0.658%
Capital International Investors	6/30/2026	4,210,221	1.238%
Fmr Llc	6/30/2026	2,478,527	-32.897%
Capital World Investors	6/30/2026	2,249,582	38.633%
Citadel Advisors Llc	6/30/2026	1,425,517	38.092%
Temasek Holdings (Private) Ltd	6/30/2026	845,729	-1.961%
Price T Rowe Associates Inc /Md/	6/30/2026	758,752	40.57%
Blackrock, Inc.	6/30/2026	694,618	5.645%
Millennium Management Llc	6/30/2026	543,323	165.235%

Previous close: 384.50 USD
Day range: 382.62 – 388.66 USD
52-week range: 253.95 – 388.66 USD
Volume: 548,932
Market cap: $43.94B
Average volume: 372,998
P/E ratio: 67.0
EPS (FY 2025, diluted): 0.19 USD
Shares outstanding: 113.70M
Beta (5Y monthly): 0.64

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 20:00 UTC· 13 hours ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 08:09 UTC· 1 hour ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for ONC yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.